The objective of the study is to evaluate: 1. Safety and efficacy of a novel foldable capsular scleral buckle (FCSB) in scleral buckling for primary rhegmatogenous retinal detachment (RRD) of medium complexity. 2. Comparison between FCSB and pars plana vitrectomy in therapeutic effects and complications in the treatment of primary RRD of medium complexity.
Pars plana vitrectomy (PPV) and scleral buckling (SB) are major choices in treating rhegmatogenous retinal detachment (RRD) of medium complexity. PPV is more prevailed since it improved internal search for breaks and elimination of vitreous traction. SB has unmatched advantages over PPV such as earlier rehabilitation, free from prolonged positioning, less complicated cataract or glaucoma. The novel foldable capsular scleral buckle (FCSB) can create a big bulge by pressing on the sclera and seal the break in bullous RRD without scleral drainage. In the study, differences of anatomic and functional results between PPV and FCSB in treating primary RRD of medium complexity are evaluated.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Using foldable capsular vitreous body as a novel scleral buckle material to treat the primary rhegmatogenous retinal detachment (RRD) of medium complexity
Using vitrectomy to treat primary rhegmatogenous retinal detachment (RRD) of medium complexity.
EyeEntFudan
Shanghai, Shanghai Municipality, China
anatomic success rate
The success rate of retinal reattachment
Time frame: From enrollment to the end of treatment at 6 months
metamorphopsia
metamorphopsia is measured by M chart
Time frame: From enrollment to the end of treatment at 6 months
Visual Results
Best-Corrected Visual Acuity, and is measured by Snellen Chart, EDTRS Chart and charts designed for people with low vision
Time frame: From enrollment to the end of treatment at 6 months
The number of surgeries that achieved successful final retinal reattachment
The number of surgeries the patient undergoes to achieve final retinal reattachment
Time frame: From enrollment to the end of treatment at 6 months
Surgical Complications
Surgical Complications, included EOM dysfunction,Choroidal detachment,Clinical CME,Macular pucker,Postoperative IOP \>21 mmHg with medications
Time frame: From enrollment to the end of treatment at 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.